This trial will study a new gene therapy for hemophilia A, which is a bleeding disorder. The trial will have two parts, A and B, studying patients with and without a history of inhibitors to factor VIII, respectively.
1 Primary · 8 Secondary · Reporting Duration: 60 months
20 Total Participants · 1 Treatment Group
Primary Treatment: Valoctocogene roxaparvovec · No Placebo Group · Phase 1 & 2
Age 18+ · Male Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: